VBI Vaccines Announces Results of Annual General Meeting

By May 25, 2018 Press Releases

VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or the “Company”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on May 24, 2018 (the “Meeting”).

The total number of common shares of the Company (“Common Shares”) represented by shareholders (“Shareholders”) present in person or represented by proxy at the Meeting was an aggregate of 40,086,159 Common Shares, representing 62.42% of VBI’s issued and outstanding Common Shares as of the record date for the Meeting.

The voting results with respect to each of the following seven director nominees, as described in the Company’s proxy statement dated April 10, 2018 (the “Proxy Statement”), all of whom previously served as directors of the Company, were as follows:

Nominee Votes For % Votes Withheld %
Jeff R. Baxter 24,985,860 98.59% 356,802 1.41%
Steven Gillis 24,418,014 96.35% 924,648 3.65%
Michel De Wilde 24,992,910 98.62% 349,752 1.38%
Adam Logal 24,995,180 98.63% 347,482 1.37%
Tomer Kariv 25,030,892 98.77% 311,770 1.23%
Scott Requadt 24,999,397 98.65% 343,265 1.35%
Steven D. Rubin 19,931,897 78.65% 5,410,765 21.35%

Each of the other matters put forward before the Shareholders for consideration and approval at the Meeting, as described in the Proxy Statement, were duly approved by the requisite number of votes. The Shareholders voted in favor of setting the number of directors at seven, appointing EisnerAmper LLP as VBI’s independent registered public accounting firm for the ensuing year and authorizing the audit committee of VBI’s board of directors to fix its remuneration.

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company’s report of voting results filed on the Company’s profile on SEDAR at www.sedar.com.

About VBI Vaccines

VBI is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

VBI Contact

Nicole Anderson, Communications Executive
Phone: (617) 830-3031 x124
Email: info@vbivaccines.com

VBI Investor Contact

Nell Beattie
Chief Business Officer
Email: ir@vbivaccines.com